Device Trial Radar · NCT00909870
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Last checked: Nov 20, 2026Latest source record: Jun 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
537
Actual
Start
Jun 2009
Primary completion
May 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- OrganogenesisNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study randomly assigns patients with venous leg ulcers to receive standard therapy (compression) alone or compression plus Dermagraft(R). Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh. Patients are seen weekly until they heal or the 16-week treatment period is complete. Follow-up visits are conducted monthly for three months in order to assess patients for longer term safety.
Conditions
- Venous Leg Ulcer
Interventions
Dermagraft(R)Device
Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
ProforeDevice
Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Healing of the Study Ulcer by Week 16.Time frame: 16 weeks
Locations
70 sites in 8 countries. Site status is shown where the registry gives one.
Coastal Clinical Research, Inc.
Mobile, Alabama
Carl T. Hayden VA Medical Center
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
67 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.